GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OCSE:NOVO B) » Definitions » Cyclically Adjusted PS Ratio

Novo Nordisk AS (OCSE:NOVO B) Cyclically Adjusted PS Ratio : 12.48 (As of Jun. 04, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted PS Ratio?

As of today (2025-06-04), Novo Nordisk AS's current share price is kr466.35. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr37.38. Novo Nordisk AS's Cyclically Adjusted PS Ratio for today is 12.48.

The historical rank and industry rank for Novo Nordisk AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCSE:NOVO B' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.17   Med: 12.17   Max: 31.25
Current: 12.48

During the past years, Novo Nordisk AS's highest Cyclically Adjusted PS Ratio was 31.25. The lowest was 8.17. And the median was 12.17.

OCSE:NOVO B's Cyclically Adjusted PS Ratio is ranked worse than
94.72% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs OCSE:NOVO B: 12.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share data for the three months ended in Mar. 2025 was kr17.562. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr37.38 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted PS Ratio Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.42 16.05 17.24 22.72 17.43

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.39 30.25 22.84 17.43 12.57

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


;
;

Novo Nordisk AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novo Nordisk AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=466.35/37.38
=12.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=17.562/120.2000*120.2000
=17.562

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.236 100.300 6.275
201509 5.209 100.200 6.249
201512 5.667 99.800 6.825
201603 5.335 100.200 6.400
201606 5.404 100.600 6.457
201609 5.440 100.200 6.526
201612 5.878 100.300 7.044
201703 5.690 101.200 6.758
201706 5.830 101.200 6.925
201709 5.389 101.800 6.363
201712 5.685 101.300 6.746
201803 5.513 101.700 6.516
201806 5.637 102.300 6.623
201809 5.738 102.400 6.735
201812 6.181 102.100 7.277
201903 6.127 102.900 7.157
201906 6.301 102.900 7.360
201909 6.379 102.900 7.451
201912 6.858 102.900 8.011
202003 7.193 103.300 8.370
202006 6.398 103.200 7.452
202009 6.622 103.500 7.690
202012 6.911 103.400 8.034
202103 7.299 104.300 8.412
202106 7.163 105.000 8.200
202109 7.753 105.800 8.808
202112 8.358 106.600 9.424
202203 9.204 109.900 10.067
202206 9.065 113.600 9.592
202209 10.043 116.400 10.371
202212 10.634 115.900 11.029
202303 11.825 117.300 12.117
202306 12.060 116.400 12.454
202309 13.083 117.400 13.395
202312 14.722 116.700 15.164
202403 14.618 118.400 14.840
202406 15.242 118.500 15.461
202409 15.987 118.900 16.162
202412 19.243 118.900 19.453
202503 17.562 120.200 17.562

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk AS  (OCSE:NOVO B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novo Nordisk AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines